In another study, Shou and colleagues reported that low expression of FOXO3 was associated with poor clinical stage, increased metastasis, and poor clinical outcomes in nasopharyngeal carcinomas (NPC) [176]. This evidence concerns the gene FOXO3 and nasopharyngeal carcinoma.